Cells for Cells S.A

Cells for Cells (C4C) is a Chilean GMP/ISO 9001:2015-certified biotechnology company specializing in advanced cell therapies and extracellular vesicle (EV) manufacturing. Founded in Santiago, C4C develops and produces clinical-grade UC-MSC-based therapies and small extracellular vesicles (sEVs/exosomes) for regenerative medicine applications, with a focus on musculoskeletal conditions, hematological diseases, and longevity.

With over 1,500 patients treated across 12+ clinical trials, C4C operates one of Latin America's leading GMP biomanufacturing platforms, combining rigorous quality systems with an active clinical pipeline. Its flagship product, Cellistem, is currently used in osteoarthritis and GVHD indications, while its exosome-based programs (Exo Native, Exo Boost) are advancing toward international licensing and regulatory approval.

C4C's U.S. spinoff, EVast Bio (Delaware C-Corp), leads the international commercialization and BD strategy, targeting markets in North America, Europe, and Asia. The company's integrated model spans GMP manufacturing, clinical evidence generation, regulatory strategy, and global partnership development — positioning C4C as a regional CDMO and co-development partner for the advanced therapies sector.